Loxo Oncology, Inc. (NASDAQ:LOXO) CEO Joshua H. Bilenker sold 7,500 shares of the business’s stock in a transaction that occurred on Monday, August 14th. The stock was sold at an average price of $73.73, for a total transaction of $552,975.00. Following the completion of the transaction, the chief executive officer now owns 196,207 shares in the company, valued at approximately $14,466,342.11. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Loxo Oncology, Inc. (LOXO) traded up 0.91% during mid-day trading on Wednesday, hitting $74.19. 381,596 shares of the stock traded hands. The firm’s market capitalization is $2.21 billion. The company has a 50-day moving average of $74.75 and a 200 day moving average of $55.56. Loxo Oncology, Inc. has a 1-year low of $17.14 and a 1-year high of $83.12.

Loxo Oncology (NASDAQ:LOXO) last announced its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($1.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.99) by $0.15. During the same period in the prior year, the firm earned ($0.77) earnings per share. On average, equities research analysts anticipate that Loxo Oncology, Inc. will post ($4.34) EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This piece was first reported by Watch List News and is the sole property of of Watch List News. If you are viewing this piece on another site, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The legal version of this piece can be viewed at https://www.watchlistnews.com/loxo-oncology-inc-loxo-ceo-joshua-h-bilenker-sells-7500-shares/1496597.html.

A number of hedge funds have recently made changes to their positions in the company. Legal & General Group Plc raised its stake in shares of Loxo Oncology by 8.4% in the first quarter. Legal & General Group Plc now owns 3,682 shares of the biopharmaceutical company’s stock worth $154,000 after buying an additional 284 shares during the last quarter. Ameritas Investment Partners Inc. raised its stake in shares of Loxo Oncology by 31.3% in the second quarter. Ameritas Investment Partners Inc. now owns 1,758 shares of the biopharmaceutical company’s stock worth $141,000 after buying an additional 419 shares during the last quarter. Wells Fargo & Company MN raised its stake in shares of Loxo Oncology by 3.8% in the second quarter. Wells Fargo & Company MN now owns 16,095 shares of the biopharmaceutical company’s stock worth $1,291,000 after buying an additional 592 shares during the last quarter. Teachers Advisors LLC raised its stake in shares of Loxo Oncology by 4.3% in the fourth quarter. Teachers Advisors LLC now owns 22,139 shares of the biopharmaceutical company’s stock worth $711,000 after buying an additional 905 shares during the last quarter. Finally, Alps Advisors Inc. raised its stake in shares of Loxo Oncology by 7.4% in the second quarter. Alps Advisors Inc. now owns 23,601 shares of the biopharmaceutical company’s stock worth $1,893,000 after buying an additional 1,623 shares during the last quarter.

A number of research analysts have recently issued reports on the stock. BidaskClub upgraded shares of Loxo Oncology from a “sell” rating to a “hold” rating in a research report on Saturday. Zacks Investment Research downgraded shares of Loxo Oncology from a “buy” rating to a “hold” rating in a research report on Saturday. Ifs Securities restated an “outperform” rating on shares of Loxo Oncology in a research report on Tuesday, August 8th. Stifel Nicolaus restated a “buy” rating and issued a $94.00 price target (up previously from $71.00) on shares of Loxo Oncology in a research report on Thursday, August 10th. Finally, BTIG Research reiterated a “buy” rating and issued a $75.00 price objective on shares of Loxo Oncology in a research note on Thursday, August 3rd. Two equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $79.67.

Loxo Oncology Company Profile

Loxo Oncology, Inc is a biopharmaceutical company. The Company is focused on development of medicines for patients with genetically defined cancers. The Company’s pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect.

Insider Buying and Selling by Quarter for Loxo Oncology (NASDAQ:LOXO)

Receive News & Ratings for Loxo Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loxo Oncology Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.